InteRNA Technologies announced this week that it and collaborators from industry and academia have received a €1.2 million ($1.6 million) grant from the European Union to form a consortium to develop its microRNA-based treatment for head and neck cancer.

Called MiRacle, the effort will combine a miRNA mimic identified by InteRNA for its ability to kill cancer cells with a delivery technology created by Israeli firm Quiet Therapeutics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.